Abstract
Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.
| Original language | English |
|---|---|
| Pages (from-to) | 935-940 |
| Number of pages | 6 |
| Journal | Surgery today |
| Volume | 41 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 1 2011 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
Cite this
The prognostic significance of chemotherapy for stage IV gastric cancer patients : A single-institution experience. / Okuyama, Toshiro; Korenaga, Daisuke; Koushi, Kenichi; Itoh, Shinji; Kawanaka, Hirofumi; Ikeda, Yasuharu; Takenaka, Kenji.
In: Surgery today, Vol. 41, No. 7, 01.07.2011, p. 935-940.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The prognostic significance of chemotherapy for stage IV gastric cancer patients
T2 - A single-institution experience
AU - Okuyama, Toshiro
AU - Korenaga, Daisuke
AU - Koushi, Kenichi
AU - Itoh, Shinji
AU - Kawanaka, Hirofumi
AU - Ikeda, Yasuharu
AU - Takenaka, Kenji
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.
AB - Purpose: The significance of aggressive chemotherapy for stage IV gastric carcinoma was retrospectively examined. Methods: This study analyzed 94 stage IV gastric cancer patients who underwent surgery with or without subsequent chemotherapeutic treatment. There were 29 potentially curative patients classified as Curability B and 65 noncurative patients classified as Curability C. These patients were divided into three groups chronologically according to the primary type of drugs administered as the 1st (1989-1998), the 2nd (1999-2002), and the 3rd term (2003-2005). Results: There was no significant difference in the survival time among the three groups (n = 94). The survival time of the patients classified as Curability C (n = 65) in the 3rd-term group (n = 17) was longer than that of the other two groups (P < 0.05). Similarly, the survival time in patients who were given new drugs and regimens (n = 22) was longer than that in those who were not (n = 43) in Curability C (P < 0.05). A multivariate analysis proved that the administrations of new drugs and regimens were independent factors for the prolongation of survival times for patients undergoing noncurative surgery (P < 0.01). Conclusions: These findings suggested that the administration of new anticancer drugs might bring about a favorable outcome for stage IV gastric cancer patients, especially in those with evidence of a residual tumor.
UR - http://www.scopus.com/inward/record.url?scp=79960303510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960303510&partnerID=8YFLogxK
U2 - 10.1007/s00595-010-4403-0
DO - 10.1007/s00595-010-4403-0
M3 - Article
C2 - 21748609
AN - SCOPUS:79960303510
VL - 41
SP - 935
EP - 940
JO - Surgery Today
JF - Surgery Today
SN - 0941-1291
IS - 7
ER -